Sort   by:  
 Page size 
ProteomicsTargeted delivery of tumor necrosis factor in combination with lomustine induces a T-cell dependent regression of glioblastoma
Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies. Here we report that the combination of L19TNF, an antibody-cytokine fusion protein based on tumor necrosis factor that selectively localizes on the tumor neo-vasculature, with the alkylating agen...
ORGANISM(S): Mus musculus (Mouse) 
2026-02-23 | PXD041234 | Pride
Immunocytokine Glioblastoma Proteomics Immunotherapy 
ProteomicsA tissue-based draft map of the murine MHC class I immunopeptidome
The array of peptides presented to CD8+ T cells by major histocompatibility complex (MHC) class I molecules is referred to as the MHC class I immunopeptidome. Although the MHC class I immunopeptidome is ubiquitous in mammals and represents a critical component of the adaptive immune system, very lit...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2020-02-19 | MSV000084980 | MassIVE
ProteomicsSequence context specific DNA de-methylation shapes progression of IDH mutant oligodendrogliomas and astrocytomas
Background: Aggressiveness guides treatment in IDH-mutant gliomas. Objective grading of oligodendrogliomas is therefore urgently needed. Material and Methods: 211 primary and recurrent resections from 111 oligodendroglioma patients were collected, complemented with 91 samples for validation. Samples...
ORGANISM(S): Homo sapiens (Human) 
2026-01-19 | PXD070222 | Pride
Lc-ms Oligodendroglioma Idh-mutant 
TranscriptomicsGATA-1-regulated erythroid microRNAs
We employed a gene complementation strategy combined with microarray screening to identify miRNAs involved in the formation of erythroid (red blood) cells. To search for GATA-1-regulated erythroid miRNAs, we used the Gata-1– erythroblast line G1E. These cells proliferate in culture as immature ery...
ORGANISM(S): Mus musculus 
2008-02-05 | E-GEOD-10134 | biostudies-arrayexpress
ProteomicsThe FFPE samples of the primary vs. recurrent glioblastoma validation cohort
The FFPE samples of the primary vs. recurrent glioblastoma validation cohort
ORGANISM(S): Homo Sapiens 
2022-08-08 | PXD035867 |
ProteomicsHigh-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity
Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here syste...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
MSV000090357 | MassIVE
ModelsDiego2021 - Improved Prediction of ICB Efficacy Across Multiple Cancer Types using Random Forests
In this study, the authors had developed a machine learning model to predict immune checkpoint blockade (ICB) response by integrating genomic, molecular, demographic and clinical data from a curated cohort (MSK-IMPACT) with 1479 patients treated with ICB across 16 different types of cancer. This mod...
2024-07-23 | MODEL2407210002 | BioModels
Machine Learning Model 
ModelsChowell2022 - Random Forest model to predict efficacy of immune checkpoint blockade across multiple cancer patient cohorts
This is a Random Forest algorithm-based machine learning model called RF16, which incorporates a total of 16 genomic, molecular, demographic, and clinical features to predict the immunotherapy response for a patient. The model assigns a value of 0 for NonResponder and 1 for Responder. Please be awar...
2023-05-09 | BIOMD0000001066 | BioModels
Machine Learning Model FAIR-AIML 
UnknownDe novo mutations across 1,465 diverse genomes reveal mutational insights and reductions in the Amish founder population.
Not available
S-EPMC7007577 | biostudies-literature
Unknown20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Not available
S-EPMC5734609 | biostudies-literature
Sort   by:  
 Page size